Please Wait...

Biomarker Analysis

The use of biochemical markers as surrogate endpoints for measuring the effects of investigational compounds and monitoring disease progression has increased significantly over the last decade.

Bioclinica Lab has extensive experience with efficacy biomarkers, predictive biomarkers, and safety biomarkers. We offer more than 70 biochemical assays performed with manual and/or automated methods and determine the most suitable method for each biomarker according to performance and test kits. Our facilities are equipped with state of the art robotics and a dedicated laboratory space for performing radioactive assays. Using Multiplex technology, we offer our clients the ability to monitor several biomarkers in parallel.

Our biomarker assays include:
ELISA
Radioimmunoassays (IRMA, RIA)
ECLIA
CLIA
Colorimetric
Immunoturbidimetric
Multiplex (MagPix)
Our comprehensive biomarker panel
spans many therapeutic areas including:
Bone and Cartilage diseases
Oncology
Cardiovascular disease
CNS diseases (Alzheimer's)
Infectious diseases
Inflammatory and Immunological diseases
Metabolic diseases (Diabetes)

All Bioclinica Lab assays are validated and qualified in-house according to a rigorous evaluation process and current international guidelines. We can also perform assay validation of customer-selected biomarkers or adapt assays to special biological matrices (e.g. synovial fluid or BALF).

Assay Validation

Bioclinica Lab validates each kit/method used for biomarker detection in a clinical study. Using assay validation, we objectively establish the reliability of a particular analytical method and ensure the accuracy and reliability of results.

A validation report summarizes the results of a test performance at Bioclinica Lab compared to manufacturer's data.

  • assay procedures
  • intra- and inter- assay variations, recovery, linearity and limits of detection
  • biomarker stability in a specific matrix for storage conditions and freeze-thaw cycles
  • expected values for population type (if data are available)

 

Prior to validation, we recommend a feasibility study to our clients for evaluating the potential of a method in a regulatory compliant environment. Bioclinica Lab will objectively qualify biomarker performance using a series of tests including dosage linearity and selectivity for a specific biomarker in a chosen matrix. At the end of a feasibility study, Bioclinica Lab will determine confidence in the chosen method and suitability for use in clinical trials.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

https://t.co/UZQTot9ovJ
bioclinica (13 hours ago)
RT @Xtalks: When is Central Imaging Needed in #ClinicalTrials? @bioclinica https://t.co/fYGvqU46TI
bioclinica (13 hours ago)
RT @phillytechnews: 11/7: BioClinica, USA Technologies buy California firms ; First Round names female general partner https://t.co/MAvm6…
bioclinica (13 hours ago)
RT @eClinical_Jen: Content from the FDA Webinar on Study Data Technical Conformance Guidelines is here: https://t.co/14eepSOR7b #ITTX17
bioclinica (13 hours ago)
RT @CenterWatch: .@US_FDA approves first #digital pill with sensor to track #patients adherence, https://t.co/XaEctKIFRx
bioclinica (13 hours ago)
RT @RAPSorg: Could you use a mid-week laugh? Many #regulatory pros will appreciate this one, courtesy of @CharlesTam https://t.co/8WxeftiCPv
bioclinica (14 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices